Benchmark downgraded AbCellera to Hold from Buy after the company reported lower results for Q3 and said it is now focusing on non-COVID partnerships and internal R&D programs. The firm’s lower rating is due to an expected longer time horizon for significant events following the end of COVID-19 related royalty revenue streams, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABCL:
